ELOX (Eloxx Pharmaceuticals) Scaled Net Operating Assets: -5.27 (As of Dec. 2025)

What is Eloxx Pharmaceuticals Scaled Net Operating Assets?

Eloxx Pharmaceuticals ELOX +5.57% 17 Scaled Net Operating Assets is -5.27 as of Dec. 2025. GuruFocus rates ELOX with a GF Score™ of 17/100. The stock has 1 warning sign investors should review.

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Eloxx Pharmaceuticals's operating assets for the quarter that ended in Dec. 2025 was $0.48 Mil. Eloxx Pharmaceuticals's operating liabilities for the quarter that ended in Dec. 2025 was $16.18 Mil. Eloxx Pharmaceuticals's Total Assets for the quarter that ended in Dec. 2024 was $2.98 Mil. Therefore, Eloxx Pharmaceuticals's scaled net operating assets (SNOA) for the quarter that ended in Dec. 2025 was -5.27.

Eloxx Pharmaceuticals Scaled Net Operating Assets Related Terms

Eloxx Pharmaceuticals Scaled Net Operating Assets Historical Data

* Premium members only.

The historical data trend for Eloxx Pharmaceuticals's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Eloxx Pharmaceuticals Scaled Net Operating Assets Chart

Eloxx Pharmaceuticals Annual Data

Trend

Jun16

Jun17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

Scaled Net Operating Assets

Get a 7-Day Free Trial

-0.24

-0.37

-0.94

-10.47

-5.27

Eloxx Pharmaceuticals Semi-Annual Data
	Jun06	Jun07	Jun08	Jun09	Jun10	Jun11	Jun12	Jun13	Jun14	Jun15	Jun16	Jun17	Dec18	Dec19	Dec20	Dec21	Dec22	Dec23	Dec24	Dec25
Scaled Net Operating Assets	Get a 7-Day Free Trial															-0.24	-0.37	-0.94	-10.47	-5.27

ELOX vs CPMV, OGEN, CASIF: Scaled Net Operating Assets Comparison

For the Biotechnology subindustry, Eloxx Pharmaceuticals's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Eloxx Pharmaceuticals Scaled Net Operating Assets vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Eloxx Pharmaceuticals's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where Eloxx Pharmaceuticals's Scaled Net Operating Assets falls into.

Save Embed

17GF Score

Eloxx Pharmaceuticals Inc ELOX

Scaled Net Operating Assets is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Eloxx Pharmaceuticals Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Eloxx Pharmaceuticals's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2025 is calculated as

	Scaled Net Operating Assets (SNOA)		(A: Dec. 2025 )
=	(Operating Assets (A: Dec. 2025 )	-	Operating Liabilities (A: Dec. 2025 ))	/	Total Assets (A: Dec. 2024 )
=	(0.485	-	16.177)	/	2.976
=	-5.27

where

	Operating Assets		(A: Dec. 2025 )
=	Total Assets	-	Cash, Cash Equivalents, Marketable Securities
=	5.27	-	4.785
=	0.485

	Operating Liabilities		(A: Dec. 2025 )
=	Total Liabilities	-	Long-Term Debt & Capital Lease Obligation	-	Short-Term Debt & Capital Lease Obligation
=	17.177	-	0	-	1
=	16.177

Eloxx Pharmaceuticals's Scaled Net Operating Assets (SNOA) for the quarter that ended in Dec. 2025 is calculated as

	Scaled Net Operating Assets (SNOA)		(Q: Dec. 2025 )
=	(Operating Assets (Q: Dec. 2025 )	-	Operating Liabilities (Q: Dec. 2025 ))	/	Total Assets (Q: Dec. 2024 )
=	(0.485	-	16.177)	/	2.976
=	-5.27

where

	Operating Assets		(Q: Dec. 2025 )
=	Total Assets	-	Cash, Cash Equivalents, Marketable Securities
=	5.27	-	4.785
=	0.485

	Operating Liabilities		(Q: Dec. 2025 )
=	Total Liabilities	-	Long-Term Debt & Capital Lease Obligation	-	Short-Term Debt & Capital Lease Obligation
=	17.177	-	0	-	1
=	16.177

Frequently Asked Questions Learn more about Scaled Net Operating Assets →

What does a Scaled Net Operating Assets of -5.27 mean?

Eloxx Pharmaceuticals (ELOX) has a Scaled Net Operating Assets of -5.27 as of Dec. 2025. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Eloxx Pharmaceuticals and its competitors.

Is Eloxx Pharmaceuticals' Scaled Net Operating Assets too high?

Eloxx Pharmaceuticals' current Scaled Net Operating Assets is -5.27. Overall, Eloxx Pharmaceuticals has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.

How does Eloxx Pharmaceuticals' Scaled Net Operating Assets compare to CPMV and OGEN?

Eloxx Pharmaceuticals' Scaled Net Operating Assets of -5.27 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Scaled Net Operating Assets for a Biotechnology company?

A good Scaled Net Operating Assets depends on the Biotechnology industry context. However, Scaled Net Operating Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Scaled Net Operating Assets mean?

A high Scaled Net Operating Assets can signal that a stock is expensive relative to its fundamentals. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Eloxx Pharmaceuticals and its competitors. Eloxx Pharmaceuticals's current Scaled Net Operating Assets is -5.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Eloxx Pharmaceuticals stock overvalued right now?

Eloxx Pharmaceuticals (ELOX) has a current Scaled Net Operating Assets of -5.27. The current Scaled Net Operating Assets is -5.27. Eloxx Pharmaceuticals' overall GF Score™ is 17/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Scaled Net Operating Assets calculated?

Scaled Net Operating Assets is calculated from a company's financial statements. For Eloxx Pharmaceuticals (ELOX), the current Scaled Net Operating Assets is -5.27 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Eloxx Pharmaceuticals Business Description

Industry Healthcare Biotechnology

Comparable Companies CPMV OGEN CASIF VBIO JAGX BBLG PKTX SLXN CLDI CMND VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY RVMD ASX:CSL ONC XKRX:068270

Address 10 Court Street, P.O. Box 274, Arlington, MA, USA, 02476

Website https://www.eloxxpharma.com

Eloxx Pharmaceuticals Inc is a clinical-stage biopharmaceutical company engaged in developing novel, small-molecule product candidates designed to modulate the ribosome and promote readthrough of premature stop codons induced by nonsense mutations (NMs) to enable the production of full-length proteins. The exaluren, the company's investigational drug product for the treatment of rare kidney diseases, and, through the collaboration with Almirall, S.A. (Almirall), ZKN-013 for the treatment of rare skin diseases.

17GF Score

Get the complete analysis for ELOX

Scaled Net Operating Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$12.05

Price

View ELOX Analysis

See Scaled Net Operating Assets data for all stocks →